PAM Deficiency Links Sarcopenia and Diabetes Mellitus Development

Overview

Loss-of-function variants in the PAM gene significantly reduce PAM enzyme activity, leading to impaired insulin secretion, increased growth hormone levels, and reduced muscle mass and function. These changes culminate in a sarcopenic diabetic phenotype, with a notable 30% increased risk of sarcopenia independent of age and diabetes status.

Background

Peptidylglycine-α-amidating monooxygenase (PAM) is essential for activating peptide hormones through amidation, impacting endocrine functions such as insulin secretion and growth hormone regulation. Genetic variants causing PAM deficiency have been linked to type 2 diabetes and altered hormone secretion. This study investigates the population-level effects of PAM loss-of-function mutations on metabolic and muscle-related phenotypes using large cohort data. Understanding PAM's role may reveal novel therapeutic targets for sarcopenic diabetes.

Data Highlights

Key Findings

• Two PAM gene loss-of-function variants, Ser539Trp and Asp563Gly, significantly reduce PAM amidating activity by 2.33 and 0.98 standard deviation units, respectively.
• Carriers of these variants show impaired insulin secretion and an increased risk of developing type 2 diabetes.
• Elevated growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels were observed in PAM LoF carriers, suggesting endocrine dysregulation.
• Reduced muscle mass and function were noted in carriers, leading to a 30% higher risk of sarcopenia independent of age and diabetes.
• The Ser539Trp variant independently increases sarcopenia risk, highlighting a direct link between PAM deficiency and muscle degeneration.

Clinical Implications

Early genetic screening for PAM loss-of-function variants can identify individuals at risk for sarcopenic diabetes, enabling timely interventions. Targeted exercise programs may mitigate muscle loss in these patients. Furthermore, development of therapies aimed at restoring PAM enzymatic activity could address both metabolic and muscle-related complications.

Conclusion

PAM deficiency due to genetic loss-of-function variants creates a distinct prediabetic sarcopenic phenotype characterized by impaired insulin secretion and muscle degeneration. Recognizing and targeting this pathway offers promising avenues for prevention and treatment.

References

1. Original Study -- Role of Peptidylglycine-alpha-amidating Monooxygenase Deficiency in the Development of Sarcopenic Diabetes Mellitus